DiRaimondo Thomas
SEC insider (Form 3/4/5 filer). CIK 0002005618. Chief Scientific Officer at Janux Therapeutics, Inc. (JANX). 5 reported Form 4/5 transactions since Sep 2024; latest on Jan 2, 2026. Located in SAN DIEGO, CA.
Companies DiRaimondo Thomas has filed insider reports for
- Janux Therapeutics, Inc. (JANX): Officer, Chief Scientific Officer
DiRaimondo Thomas
CIK: 0002005618
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)3 (60.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)2 (40.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
JANX
Janux Therapeutics, Inc.
Officer
Discretionary Trading P&L
Holdings
Transaction History (5 total)
- Jan 2, 2026JANX
Janux Therapeutics, Inc.
SaleDirect2.5K shares at avg. $13.73$34K - Jan 2, 2026JANX
Janux Therapeutics, Inc.
AwardDirect31.4K shares- - Jan 2, 2025JANX
Janux Therapeutics, Inc.
AwardDirect24K shares- - Sep 27, 2024JANX
Janux Therapeutics, Inc.
SaleDirect4.3K shares at avg. $46.21$200K - Sep 27, 2024JANX
Janux Therapeutics, Inc.
SaleDirect675 shares at avg. $47.22$32K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jan 2, 2026 | JANX Janux Therapeutics, Inc. | Sale | 2,505 | $13.73 | $34,394 | Direct |
| Jan 2, 2026 | JANX Janux Therapeutics, Inc. | Award | 31,400 | - | $0 | Direct |
| Jan 2, 2025 | JANX Janux Therapeutics, Inc. | Award | 24,000 | - | $0 | Direct |
| Sep 27, 2024 | JANX Janux Therapeutics, Inc. | Sale | 4,325 | $46.21 | $199,840 | Direct |
| Sep 27, 2024 | JANX Janux Therapeutics, Inc. | Sale | 675 | $47.22 | $31,877 | Direct |
1-5 of 5 transactions